Mengis Capital Management, Inc. Vertex Pharmaceuticals Inc Transaction History
Mengis Capital Management, Inc.
- $456 Million
- Q2 2025
A detailed history of Mengis Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mengis Capital Management, Inc. holds 500 shares of VRTX stock, worth $201,650. This represents 0.05% of its overall portfolio holdings.
Number of Shares
500Holding current value
$201,650% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,809Shares Held
239MCall Options Held
1.95MPut Options Held
1.14M-
Capital World Investors Los Angeles, CA28.7MShares$11.6 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$9.67 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.6 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.1MShares$6.5 Billion1.5% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.75 Billion0.2% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $104B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...